Inside Wall Street: Newly Independent Mead Johnson Could Be Buyout Bait
{ Posted on Jan 13 2010 by Gene Marcial }
Mead Johnson (MJN) is getting a lot of fresh attention on Wall Street. Now an independent publicly traded company after Bristol-Myers Squibb (BMY) sold its controlling 83% stake in December, Mead is attracting new interest not just because of its ...Read More »
Unique in the industry, Macroaxis financial engineering platform delivers measurable value in the form of improved return on your investment portfolios | 

